VTVT vTv Therapeutics

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns related to the COVID-19 pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others.

The previously announced date and time of the Annual Meeting, Thursday, June 11, 2020 at 9:00 a.m. Eastern Daylight Time, as disclosed in the previously distributed Notice of the Annual Meeting and Definitive Proxy Statement (the "Notice and Proxy Statement"), has not changed. Stockholders will not be able to attend the Annual Meeting in person.  A notice regarding this change to a virtual meeting format is being filed with the Securities and Exchange Commission together with this press release.

Registering and Asking Questions

In order to attend the Annual Meeting, vTv stockholders of record as of April 20, 2020 must register in advance by accessing .  During the registration process, you may submit a question regarding the business of the meeting. Questions submitted in advance will be answered depending on the availability of time and members of management present at the Annual Meeting. All registrations and questions from stockholders must be received by 5:00 p.m. Eastern Daylight Time on Tuesday, June 9, 2020. After completing your registration by the registration deadline, further instructions, including a link to access the Annual Meeting, will be emailed to you.

Attending the Meeting

Online access to the Annual Meeting will begin 15 minutes prior to the meeting start time of 9:00 a.m. Eastern Daylight Time on June 11, 2020. To be admitted to the Annual Meeting's live webcast, you must have previously registered at by the registration deadline of Tuesday, June 9, 2020 at 5:00 p.m. Eastern Daylight Time.

Voting

All stockholders, whether or not planning to attend the virtual Annual Meeting, are encouraged to vote promptly in advance of the meeting by using one of the methods described in the proxy materials for the Annual Meeting. The proxy card and voting instruction form included with the previously distributed proxy materials (or notice of internet availability) will not be reissued and may continue to be used to vote shares in connection with the Annual Meeting.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases.

Contacts

Investors:

Corey Davis

LifeSci Advisors

or



Media:

Glenn Silver

Lazar FINN Partners

646-871-8485

EN
22/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61s...

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonist HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organizatio...

 PRESS RELEASE

UPDATE -- vTv Therapeutics to Participate in Upcoming September Invest...

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investo...

 PRESS RELEASE

vTv Therapeutics to Participate in Upcoming September Investor Confere...

vTv Therapeutics to Participate in Upcoming September Investor Conferences HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences: H.C. Wainwright 27th Annual Global Investment ConferenceDate:Tuesday, September 9, 2025Format:1x1 Investor Meetings...

 PRESS RELEASE

vTv Therapeutics Announces $80 Million Private Placement with Leading ...

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, poten...

 PRESS RELEASE

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Pro...

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •   First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 •   Cadisegliatin intellectual property portfolio expanded •   Leadership team strengthened HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch